The drug Zometa (brand name, zoledronic acid) recently received approval by the U.S. Food and Drug Administration (FDA) to treat elevated calcium levels (hypercalcemia of malignancy, HCM). HCM is a complication that can occur in cancer patients, including those with advanced breast cancer whose cancer has spread past the breast and lymph nodes to the bone. The FDA is also considering approving market authorization of Zometa to treat bone metastases (cancer that has spread to the bone) in patients with breast cancer and other cancers. Clinical trials of Zometa show that it may be more effective than the drug Aredia, the standard treatment for bone metastases. Euro Cancer Conference, 10/01 Anti-tumor activity of Pamidronate/Multiple Myeloma Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.